

INVENTIVE ACTIVITY FY2016

Northwestern INVO







DEAR MEMBERS OF THE NORTHWESTERN COMMUNITY.

At Northwestern University, innovation is not a buzzword. Innovation is our reality.

Led by faculty and students and collaborative partnerships determined to solve pressing problems, our diverse and multidimensional innovation ecosystem cuts across our Evanston and Chicago campuses with a creative, vibrant, and persistent energy. INVO helps fuel this world, identifying technology with compelling potential, adding value through resources such as coaching and IP protection, and then capturing value in the marketplace.

This past year, FY16, showed no slowdown in invention disclosures, filed patents, and deals, though the year might best be remembered as a key inflection point in student innovation. As our students increasingly eager for a taste of entrepreneurial adventure—captured national competitions and landed spots in prestigious accelerator programs, Northwestern and INVO celebrated the debut of The Garage, our hub for student entrepreneurship, as well as the launch of NUseeds, a multi-million dollar VC fund to boost promising early-stage ventures from students. It's a bet on the future—and one placed with strong confidence in our people.

Throughout this report's pages, you will see stories of accelerating areas of inventive strength at Northwestern in fields such as wearables, ALS, and depression; details of new programs designed to drive innovation, such as the Northwestern Women Innovator Initiative (N.Wii) and N.XT, the first building block for the development of faculty-led, science-driven inventions; and the metrics that landed Northwestern another top-10 nod in Reuters' annual rankings of the world's most innovative universities.

To be certain, the past energizes us, but it is the spectacular enthusiasm, surging momentum, and substantial vision of our institution that inspires our excitement for the future. With strategic nurturing, unrelenting drive, and steadfast support, we know that today's discoveries will deliver tomorrow's game-changing results and move more and more Northwestern innovations to market.

Know our innovative spirit is higher than ever. Know our future is bright. Know there is much, much more to come. Know We Will.

Alicia Löffler Executive Director, INVO Associate Provost, Innovation and New Ventures Associate Vice President for Research

KNOW OUR INNOVATIVE SPIRIT IS HIGHER THAN EVER. KNOW OUR FUTURE IS BRIGHT.



169



2,22 MILLION IN EQUITY SALES, DOLLARS





130

MILLION IN RESEARCH

FUNDED BY STARTUPS

NORTHWESTERN INVENTIVE ACTIVITY CONTINUED STRONG

Figure 1 illustrates invention disclosure activity since 2002. In FY16, INVO processed 202 invention disclosures, similar to the FY15 level (212). This minor adjustment might reflect the fact that in FY16, INVO, through The Garage, began providing invention waivers to students before they disclose. This change in process was established to reduce the administrative burden on the INVO office.

Figure 2 represents the distribution of inventive activity per school. The McCornick School of Engineering (McC) and the Feinberg School of Medicine (FSM) have the largest shares, followed by the Weinberg College of Arts and Sciences (WCAS).

Inventorship spans both campuses.

Inventions span many disciplines and markets. Figure 3 shows the distribution of inventions by category. Biomedical inventions

Figure 1. Invention disclosures, 2002–2016

on diagnostics) continued to be the largest share of the inventive output. er It is important to note that many inventions in the areas of chemistry, computer science, and materials are considered olatform technol-

(therapeutics, medical devices, and

ogies with undefined markets. For example, a new software invention might find applications in the future in a variety of markets such as energy, consumer, and biomedical.




Figure 2. Inventions by school





Figure 3. Inventions by category





HANGING THE SOLAR CELL MARKET Professor Mercouri G. Kanatzidis (Weinberg) knew there had to be a better way. Though perovskite solar cells had shown compelling promise since 2012, reenergizing the solar field and leading some to call the technology "the next big thing in photovoltaics," the mainstream potential of the technology faced a glaring obstacle: the presence of toxic lead.

A seminal publication in 2012 helped to spark the field of perovskites. This pushed Kanatzidis—an inorganic chemist—and his Northwestern team of researchers, including nanoscientist Robert Chang (McCormick), to develop a lead-free alternative. In 2014, Kanatzidis' group found early success by swapping lead for tin as the harvester of light. Subsequent innovation from the Kanatzidis-directed team has spurred significant interest from both public and private enterprise, particularly given that Kanatzidis' technology requires neither elaborate equipment nor hazardous materials.

Currently, Kanatzidis' lab is working to raise the efficiency levels of its tin solar cells to 10 percent, specifically seeking ways to extract extra voltage from the post-transition metal. They are also working to prepare a stable device that can be further developed into a panel. Success in those efforts, Kanatzidis says, will help him license the technology or secure a partnership to accelerate the discovery process.

"Solar energy is the only sustainable energy and we hope to translate our discovery to the broad-based distribution of solar energy panels that convert sunlight to electricity for homes and businesses in a more environmentally friendly way and at a lower cost than presently available," says Kanatzidis. He is also working with INVO on two other environmental projects, one that removes radioactive elements from nuclear waste and another that cleans industrial water from toxic metals.

Professors Mercouri Kanatzidis (middle) and Robert Chang (right) discuss solar-cell preparation methods with graduate student Byunghong Lee. Photo Credit: Mitch Jacoby/C&EN

COLLABORATION IS ONE OF THE PILLARS OF HIGH QUALITY INVENTIONS

FIGURE 4. Boundary crossing ideas produced the most disruptive inventions, which are also most valued in the marketplace. Northwestern's interdisciplinary approach is displayed by the high level of co-inventorship activity among different schools.



INVENTORSHIP OCCURS IN ALMOST ALL DEPARTMENTS WITHIN THE SCHOOLS

Figures 5, 6 and 7 illustrate inventive activity within each school.

10 Northwestern INVO

Figure 5. McCormick School of Engineering inventions by department




Figure 6. Feinberg School of Medicine inventions by department





Figure 7. Weinberg College of Arts and Sciences inventions by department





and it's one with deep pockets, NUseeds. Earlier this year, the University awarded the first two NUseeds investments, a S4 million venture capital fund providing seed investments to accelerate the launch of the most promising student-founded, early-stage ventures.

Pakd, the brainchild of Kellogg students Nate Cooper '17 and Rebecca Sholiton '16, received a \$75,000 investment, which the startup is devoting to growing its user base and driving expansion outside of the Chicago area. Specifically targeting parents of the school-aged crowd and pledging to eliminate the frustrating work of preparing school lunches, Pak'd delivers fresh, customizable lunches directly to homes.

Another Kellogg student, Blair Pircon '16, received \$40,000 for her venture, The Graide Network. The online platform connects teachers with university students studying education—so-called "Graiders" to provide additional feedback on student work ranging from essays to computer science projects. Pircon has earmarked her NUseeds award for the hiring of personnel tasked to recruit and onboard new Graiders.

In addition to the capital infusion, both Pak'D and The Graide Network receive coaching from a network of external alumni and community experts at The Garage, Northwestern's one-year-old, on-campus innovation hub for students.

Future NUseeds recipients will come from The Garage's collection of student-founded startups and its Wildfire accelerator program, while award candidates will continue to be evaluated and selected by an external investment committee comprised of professional investors.

"With NUseeds, we're placing a bet on our best and most talented student entrepreneurs and showing that we're engaged in driving the growth of their ventures." —Melissa Kaufman, Executive Director, The Garage

The Graide Network co-founders, Liz Nell (left) and Kellogg MBA student Blair Pircon (right) tied for first in the Northwestern University Venture Challenge.



.WII: SUPPORTING WOMEN INNOVATORS Compared to their male counterparts across the broader entrepreneurial landscape, female innovators remain less likely to disclose inventions, to patent, and to engage in entrepreneurial activity.

With its Northwestern Women Innovator Initiative (N.Wii), INVO looks to challenge that global reality, discarding myths about entrepreneurship, empowering female innovation and inventorship, and increasing the number of Northwestern female faculty in the entrepreneurial ranks by 30 percent over the next three years.

With a soft launch in late 2015, N.Wii takes aim at those numbers, helping female innovators become inventors and female inventors become entrepreneurs or board members, particularly in the STEM and life science fields.

The initiative confronts two common impediments to female entrepreneurial success: uneven access to resources and the lack of a network. Through the NWii program, select female innovators will be pulled into the NVO ecosystem and its vast array of resources, including: connections to argeted role models and mentors; support in the pursuit of scholarly, funding, and promotional awards as well as commercialization grants; training for pitch sessions; access points to partners and investors; and guidance through the startup formation.

While the upstart INVO initiative is currently for targeted female faculty and staff members only, the long-term plan is to cover the entire Northwestern entrepreneurial pipeline from undergraduates to senior faculty and for N.Wii to broaden its reach with targeted programming designed to further drive female entrepreneurship.

"We know that diversity ensures we get the best innovations and increased chances of success, and NWii looks to bring greater diversity into the entrepreneurial ranks." —Dimitra Georganopoulou, INVO Innovation and Commercialization Officer

McCormick School of Engineering Professor and logistics expert Karen Smilowitz (middle) and her team of engineering students using their dashboard to collaborate with Bank of America Chicago Marathon on data analytics. Photo Credit: Bank of America Chicago Marathon

INVO LOOKS TO EMPOWER FEMALE INNOVATION AND INVENTORSHIP

Figures 8, 9 and 10 represent the gender distribution of tenured and tenure-eligible faculty and the percentage of whom have disclosed inventions during FY 2016. Weinberg College of Arts and Sciences percentages represent faculty from the departments of Chemistry, Molecular Biosciences and Neurobiology. Figure 8. Inventions McCormick School of Engineering, gender distribution




Figure 9. Inventions Feinberg School of Medicine, gender distribution




Figure 10. Inventions Weinberg College of Arts and Sciences, gender distribution





AKING WAVES IN THE WEARABLES MARKET Being an innovative force in the explosive wearables market is nothing new for Northwestern University. Innovative research from the lab of Professor Tobin Market (Weinberg) spurred the ascent of Polyera, a materials developer whose Activink technology has been applied to a diverse range of products from solar cells and sensors to RFID tags. The research of Professor Mark Hersam's (McCormick) group into premium single- and double-walled carbon nanctubes fueled NanoIntegris, a startup acquired by Raymor Industries in 2012.

In the still-nascent wearables field, Northwestern is now quickening its pace.

This year, Northwestern welcomed John Rogers (McCormick, Feinberg), a world-renowned scientist and pioneer in the field of bio-integrated electronic devices whose research is capable of changing the fields of industrial, consumer, and biocompatible electronics. By making semi-conductor devices look more and more like biology—think more temporary tattoo than wrist watch — Rogers blends the dynamic world of modern consumer electronics with human health, inspiring potential groundbreaking solutions such and implantable medical devices that can harvest energy from organs or automatically treat medical conditions.

Development of such wearable technologies is aided by one of Professor Rogers' frequent collaborators, Professor Yonggang Huang (McCormick), whose work includes establishing mechanics and thermal analysis models for stretchable and flexible electronics, epidermal electronics and transient electronics, as well as 3D fabrication of any materials.

Then, there is Bold Diagnostics, an award-winning venture fueled by the Center for Device Development's (CD2) Innovation Fellowship program. Replacing the traditional bulky arm cuff for blood pressure measurement with Bold Bands, a wearable device that provides continuous blood pressure monitoring, Bold Diagnostics aims to reduce the risk of misdiagnosis from inaccurate readings and to drive more pinpoint treatment of hypertension and other cardiovascular diseases. After a successful run in the 2016 business plan competition circuit, Bold Diagnostics captured a first-place nod in the 2016 reate the Future Design Contest, an annual global event that rewards engineering innovation.

"The CD2 Fellowship program challenges fellows—two physicians and two engineers to identify a clinical need and develop a solution within one year. With protected and paid time to develop their solution along with additional instructional support, the goal is to create meaningful medical innovations that can improve treatment and results."—Sonia Kim, Managing Director of Marketing and Commercialization Education, INVO

Top: "Tattoo electronics", flexible wireless electronics developed by Professors Yonggang Huang (McCormick) and John Rogers (McCormick, Feinherg). Bottom: The 2016 CD2 Fellows (left to right: Bean Connell, Jay Pandit, Kyle Miller and Andrew Wu) won over \$128,000 through the business plan competition circuit and received an NSF SBIR grant of \$225,000 to advance it te technology and build its next phase prototype. They benefited from the guidance of Adjunct Kallogg Lecturer Peter McNerney, INVO's Managing Director Sonia Kim as well as key physicians, professors, and staff at Northwestern University and Northwestern Memorial Hospital and the Chicago mediceh community. To their right, the Bold prototype of the Bold Band and its associated app platform.





DDRESSING DEPRESSION FROM ALL ANGLES Northwestern University is attacking depression, an oft-debilitating condition estimated to affect 6–10 percent of the U.S. population each year, from a trio of angles—therapeutics, diagnosis, and monitoring.

Researcher Joe Moskal (McCormick) led the recent charge with Rapastinel, the signature drug at his Northwestern startup Naurex. Developed to combat major depressive disorder, Rapastinel entered Phase 3 trials this past summer, about one year after global pharmaceutical giant Allergan acquired Naurex in a deal that included a \$560 million upfront payment. In previous trials, the drug captured attention as a fasteracting, longer-lasting alternative to current depression therapeutics, while also carrying fewer side effects.

Eva Redei (Feinberg), meanwhile, continues her encouraging research into depression biomarkers, heightening the potential of qualitative analysis for a condition long hampered by the limits of quantitative diagnosis. Redei's biomarkers research has displayed promising potential to identify depression's biological links and accelerate the path to—and perhaps even the acceptance of—helpful interventions.

Spurred by the work of David Mohr (Feinberg), IntelliCare tackles three of the most frequent impediments to treatment of depression and anxiety—access, affordability, and stigma—with a suite of 14 free mobile apps. The patent-pending platform targets the common causes of depression and anxiety, such as sleep problems, lack of activity, and social isolation. During a recently closed eight-week field study, nearly 100 IntelliCare subjects used the apps consistently and showed measurable improvement. IntelliCare is now in the midst of a randomized clinical trial and continues fielding potential partnership opportunities from both private and public healthcare providers.

"Professor Redei's work with biomarkers capitalizes on already-available clinical and lab tools and helps to destigmatize depression by showing there's a biological reason at play, which hopefully leads more people to seek treatment." —Mike Moore, INVO Invention Manager

IntelliCare Hub, a suite of apps developed by Professor David Mohr (Feinberg) to deliver treatment for depression and anxiety.


PATENT FILING INCREASED 17% FROM FY15 Figure 11 shows patents filed in FY16 per school. Patent filing is consistent with the invention disclosure activity reported in Figure 2. Figure 12 illustrates the breakout of patents filed in FY16.

Provisional patents: Approximately 60%-70% of all invention disclosures are filed as provisional patents; approximately 50%-60% are converted into non-provisional patents within a year.

Filing a provisional patent application before filing a Utility application presents several advantages:

- Relatively inexpensive, and allows the inventor to spend one year gathering more data resulting in a stronger patent application;
- · Allows INVO to conduct a more in depth commercial assessment of

Figure 11. Filed patent applications by school



potential licensees: and

expiration date.

· Delays the formal filing date,

Non-Provisional (Utility) patent

patent starts the official exam-

applications: The filing of a Utility

ination process with the USPTO to determine if the invention is patent-

able. The USPTO review of a patent

application can take several years.

PCT applications: A PCT is an inter-

national treaty with more than 145

Contracting States. The PCT makes

it possible to seek patent protec-

ly in a large number of countries

patent. A PCT application must be followed up within 18 months by

entering into national or regional

by filing a single "international"

tion for an invention simultaneous-

which results in a later patent

the invention and identification of phases to proceed towards grant of one or more patents. Foreign pros-ecutions are very expensive. INVO files in specific countries (National Phase) only when there is a licensee for the patent.


> Continuing patent applications (CIP): These are patent applications that follow and claim priority to an earlier filed patent application.

EPO Validation: Granted European patents that are in the process of validation in individual states.

Divisional patent applications: Patent applications with claims that were divided out of the original filed application and which have to be resubmitted as a separate application.

Figure 13 illustrates that patent filings span many disciplines and markets.





INVO Inventive Activity FY2016 23

Figure 13. Issued patent applications by category




Figure 12. Filed patent applications by type

NUMBER OF AGREEMENTS CONTINUED **TO GROW**

INVO executed 169 agreements during FY16, representing a 36% growth compared to FY15 and grown compared to F1 b and tions: license to developers or 150% increase compared to F14. Agreements ranged from inter-institutional agreements to material evaluation agreements and licenses. The volume of agreements signals a growing external interest in Northwestern's inventions.

There are two main paths to commercialize academic inven-tions: license to developers or license to spinouts. Most co-devel-opment partnerships will include needed to determine utility.

Exclusive licenses or options are generally executed for technologies that require significant private investment to reach the marketplace or are so early stage that exclusivity

Figure 14. Agreements by school




Weinberg College of Arts and Sciences School of Communication


1

Exclusive License

Non-Exclusive License



Exclusive Option



HE N.XT FRONTIER OF ALS RESEARCH AT NORTHWESTERN For more than 30 years, Northwestern University has been working to unlock the puzzle of ALS. The University's unique strength in battling the progressive neurodegenerative disease arrives from a range of dedicated researchers,

In battling the progressive neurodegenerative disease arrives from a range of dedicated researchers, including Teepu Siddique, MD (Feinberg), who spearheaded the creation of a "research standard" model system for ALS now licensed by researchers around the globe.

Professor Richard Silverman (Weinberg), the world-renowned chemist who developed the pharmaceutical now marketed as Lyrica, and Assistant Professor Hande Ozdinler (Feinberg), an expert on upper motor neuron biology, are now driving the University's latest potential game-changing ALS innovation. The promising early effort combines Ozdinler's novel approach for visualizing motor neurons in the brain with Silverman's compounds designed for the inhibition of protein aggregation, one of the hallmarks of ALS.

Silverman and Ozdinler are now taking their next research steps—more extensive *in vitro* studies and, later, *in vivo* animal studies—as the first recipients of a capital infusion from the University's \$10 million NXT fund, designed to support Northwestern's early-stage innovations and propel commercial development.

While no ALS drug has successfully emerged from clinical trials over the last two decades, Silverman and Ozdinler look to reverse that trend with their novel approach to drug discovery. By focusing on the health of the brain's motor neurons, the researchers' interdisciplinary collaboration represents the start of a paradigm shift in preclinical studies and drug discovery in ALS as well as other motor neuron diseases.

"Research often reaches a point in which the money runs out and once-promising projects fall into the valley of death. With the N.XT fund, Northwestern is providing a bridge to help innovative projects move on to later-stage development that can lead to additional investment and potential commercialization." –Nick Maull, Assistant Director of New Ventures, INVO

Professor Hande Ozdinler's visualizations of upper motor neurons in ALS mouse at different scales


NORTHWESTERN STARTUPS RAISED MORE THAN \$110 MILLION IN FY16


FIGURE 17. Entrepreneurial activity in universities is measured by the number of startups launched every year. Northwestern has consistently ranked high in this metric.

28 Northwestern INVO

An important metric for startup success is the ability to fundraise. In FY16, Northwestern startups raised more than \$110M from the private sector and signed more than \$1.5B in co-development agreements. The outstanding success of these NU startups is proven validation of the

Varitys is proven variaduoin or the quality of Northwestern's inventions. These companies included: Aptinyx (Prof. Moskal), Cour (Prof. Miller), Exicure (Prof. Mirkin), Tanvas (Profs. Colgate and Peshkin), and Transplant





 RESEARCH
 RESEARCH VALIDATION
 COMMERCIAL VALIDATION
 MARKET

 Secure Tool for Medical Data Transfer
 OR Supervision Aspector Movement Disorders
 Diagongetisenders
 Diagongetisenders

 App for Movement Disorders
 Berkhurst 6 Triage (BU Care
 Depresion Appoint Placement Algorithm
 MATLAB to C Translator

 Placement Algorithm
 Precise Automation Description Movement Disorders
 MATLAB to C Translator

 Placement Algorithm
 Precise Automation Description Movement Disorders
 MATLAB to C Translator

 Placement Algorithm
 Precise Automation Description Movement Disorder
 Big Data for Marketing Disorder Movement Disorder

 Street-level IP Geolocation Wareguide Modulators
 Encryption Technology Dimination Software Expression Software Description Technology Disorder
 Disorders

 My Dream Team
 Digital Language Lab
 Tivor/Cronkite
 Digital Language Lab

APPENDIX

30 Northwestern INVO

COMPUTER SCIENCE & COMMUNICATIONS PIPELINE Available for License Exclusive License/Option

CONCEPT & FEASIBILITY >> DEVELOPMENT >> VALIDATION >> MARKET

CONCEPT & FESSIBILITY > DEVELOPMENT > VALORITO > MARKET Analysis of Multiplexed Based-Based Assays Electronic Biochip System Junames for Multiplexed Based Based Assays Junames for Multiplexed Based Based Assays Junames for Multiplexed Presensed Cilical Parengiosa strains Junames for Multiplexed Based Based Assays Junames for Multiplexed Presensed Cilical Parengiosa strains Junames for Multiplexed Presensed Cilical Parengiosa strains Junames for Multiplexed Presensed Strains Junames for Multiplexed Presensed Strains Junames for Multiplexed Presensed Strains Junames for Surgery Presensed St

	Ferroelectronics
	-Coupled Transisto
All Carb	on Spin Logic
Two Qui	oit Gate
Comput	ing Logic Family
Polyme	rs for Protecting Ci
	ogic Family with re Transistors
	ts for Use in Next tion Solar Cells
	m Interference Mol nic Devices
Doped 1 Single C	'in Selenium Crystals
Tin-Bas Solar Ce	ed Perovskites for Als
	v Power Carbon e Logic Circuits
	ted On-Chip couple Array
	ic Diode Based nmable Logic
Transve	rse Thermoelectric
Gate Tu Memris	nable Nanoscale tors
Spin Die	de Logic Family

RESEARCH

▶ RESEARCH VALIDATION ► COMMERCIAL VALIDATION ► MARKET

 PERSEARCH VALIDATION
 > COMMERCIAL VALIDATION
 > MARKET

 Nanophotonics Directional Coupier
 Organic Sinciconductors
 > Market

 Efficient Thin Film Synthesis
 Dirganic Sinciconductors
 Proceedings of Current Flow
 Proc

from Semiconductors Magnetic Field Sensors Bridge-Enhanced Nanoscale Impedance Microscopy Tracking Circuit for Hardware Security and Configuration Deducing Charge Density Gradients in Semiconductors

DIAGNOSTICS & BIOMARKERS PIPELINE Available for License Non-Exclusive License/Option Exclusive License/Option

ELECTRONICS & SEMICONDUCTORS PIPELINE Available for License Non-Exclusive License/Option Exclusive License/Option

INVO Inventive Activity FY2016 33

▶ RESEARCH VALIDATION ► COMMERCIAL VALIDATION ► MARKET RESEARCH

Improved Lead-based Eutectic Composite SMOFC Battery Cathode Graphitized Li Ion Batteries Nanocomposites for Energy Storage Crumpled Graphene Coated Si Nanoparticles Carbon Nanoparticle for Energy Storage Novel Separator for Storage Devices Silver Containing Cathode for Li Ion Batteries

 RESEARCH
 RESEARCH VALIDATION
 COMMERCIAL VALIDATION

 Doped Tin Belenium Single Crystals
 --type Transparent Conductorn Integrated Solid Gold Fail Cell
 Hole Array Films

 Integrated Solid Gold Fail Cell
 Hole Array Films
 Novel Organic Self-Assembled

 Deport Tin Benerium Single Crystals
 Methane Powered Fail Cell
 Novel Organic Self-Assembled

 Solid Oxide Fail Cells
 Solid Oxide Fail Cells
 Novel Organic Self-Assembled

 Solid Oxide Fail Cells
 Beloton-Blocking Layer for Organic Photovoltalse with Noted Coxide
 Methane Self-Assembled

 Solid Oxide Fail Cells
 Boild Oxide Fail Cells
 More Cells

 Solid Oxide Fail Cells
 Solid Oxide Fail Cells
 More Cells

 Solid Oxide Fail Cells
 Controlling Charge Iphection for Organic Photovoltalse Oxide
 Option Countre Electrode

 All-Carbon Countre Electrode
 Lad-Free Solid Cells
 Solid Photovoltalse Cells

 More Batteries Or Medical Devicet Ingroved Law-Fail
 Solid Photovoltalse Cells
 Solid Photovoltalse Cells

 Manoempositie
 Solid Photovoltalse Cells
 More Datteries Or Medical Devicet In OLDB
 Solid Photovoltalse Cells

 More Batteries Cells
 More Datteries Or Medical Devicet Ingrovoltalse's Dased Educteris Compositie
 S

INVO Inventive Activity FY2016 35

RESEARCH > RESEARCH VALIDATION > COMMERCIAL VALIDATION > MARKET

Available for License Non-Exclusive License/Option Exclusive License/Option

ENERGY PIPELINE Available for License Exclusive License/Option

Adhesive Polymer Coating Electro-Optic Modulator Single Photon Detectors and Imagers Nano Fountain Pen

MATERIALS AND MANUFACTURING PIPELINE

PREMENT PREMENTATION Pressure Pressure data participants Pressure Pressure data participants Pressure Pressure data participants Pressure Pressure

DOPA-Melanin Films Mesoscale Metallic Pyramids with Nanoscale Tips PAH Scavenger System (ExBox) Metal Oxide Thin Film Electronics Adhesive Polymer Coating

Nahocompositor Hill data ray Production Novel Solid Organic Host Silicon Matrix Polymer Fabrication of Metal Composite Fabrication of Metal Composite Thin Films Acene-Based Semiconductor Materials Enhanced Diode Performance Method for Epitaxial Growth of MgO Solid State Shear Pulverization Process

COMMERCIAL VALIDATION NARKET Organic Electro-Optic Chromophore New Nickiel Based Alloy Gaphene Titals Nancomposite Photocativits Advanced Materials Graphene Titals Nancomposite Photocativits Tignshen Titals Nancomposite Photocativits Composite Photocativits Composite Photocativits Marce Surface Astronic Systems New Naterial for Polymer Uight Christing Uideouting Tomasite Photocatist Composite Photocativits Composite Photocativits Novel Material for Polymer Uight Christing Uideouting Charges Photocatist Composite Photocatist Composite Photocatist Removal of Metal Pollutants from Water Electron Biochyner Dielectrics Oncesting Charges Injection In OLEDs Occasitabile Photocatist Colls Chromophores Based Chromophores

CONCEPT > LABORATORY PROTOTYPE Preparie Beams Nor Filter Finorul Nor Filter Finorul Schulter For Gene Schulter For Gene</td ▷ LABORATORY PROTOTYPE ▷ COMMERCIAL PROTOTYPE ▷ HUMAN TESTING ▷ APPROVAL AND MARKETING CONCEPT Wearable for Ambulatory Blood Pressure Monitoring Intracardiac Electrogram

MEDICAL DEVICES PIPELINE

Available for License Non-Exclusive License/Option Exclusive License/Option

NANOTECHNOLOGY PIPELINE Available for License Exclusive License/Option

RESEARCH

Laser-Assisted Nanpatterning Nanodiamonds for Imaging and Drug

INVO Inventive Activity FY2016 37

Gold Nanoparticles Point of Care Diagnostics



NUCLEIC ACIDS ANTIBODIES

Mouse Rat Rabbit

CELL LINES

MOUSE MODELS MISCELLANEOUS

 NUCLEIC ACIDS
 ANTIBODIES
 CELL LINES
 MOUSE MODELS
 NISCELLANEOUS

 NUM-Directed Gene Editing Lang Gene Transfer Under Transfer Verbori
 CD31, CD37 and CD3 mdba Tubulointextea CD3 mdba Mortalia
 CD31, CD37 and CD3 mdba Tubulointextea CD3 mdba Mortalia
 CD31, CD37 and CD3 mdba Tubulointextea CD3 mdba Mortalia
 CD31, CD37 and CD3 mdba Tubulointextea CD3 mdba Mortalia
 CD31, CD37 and CD37 mdba Mortalia
 CD31, CD37 and CD37 mdba Mortalia
 CD31, CD37 and CD37 mdba Mortalia
 CD31, CD37 mdba Mortalia Cell-Free Yeast Protein Synthesia Methods for Ribosome Production Ensource Targeting Tethered Ribosome Production Enhanced Gene Silencing Scaffidds for Artificial Orary Designet Free Hembrane Solubilization Raman Spectroscopy for Anthraz Detection Mutitanalyte Detection Partificon Layer for Raman Nanobiosensor

Chromatin Therapy to	Megakaryocytic Leukemia	Kinase Inhibitors	
Sensitize CA Cells Kinase Inhibitors	Compounds Against Nodal Pathway (CA)	GLUT Antagnonists: Cancer 1	
for Cancer	p53 Reactivator: Cancer	GLUT Antagonists:	
MAPK Compounds for CNS Disorders	Peptides for CA Treatment	Cancer 2	
Racterial NOS inhibitors	Peptides for PEDF	Maspin Protein Mimi for Cancer Treatment	
as Antibiotics	Small Molecule Against ALS	Triggered Release An	
3D Printing of Endovascular Stents	Ion Channel Manipulation: Parkinsons'	Drugs for CA Inhibitors for Triple	
FGF23 Normalizing	Compounds for	Negative Breast CA	
Methods Exosomes for Cholesterol	Neurologic Disorders	Inhibitors for Leuker	
Modulation	Epstein-Barr Virus Inhibitors	Peptides for Neurodegeneration	
Female Fertility Treatment	Urinary Tract Infection Vaccine	Small Molecules for Parkinson's Disease	
Sirtuin Inhibitors	HIV Therapeutics	Neuroprotective The	
MLCK Inhibitors	Small Molecule Antiviral	Neurodegenerative	
Anti-Inflammatory Antibodies	Therapy	Disease Therapy Gene Therapy for Atr	
Pro-Drugs for Streptococcus	Plaque Digestion: Cardiovascular	Fibrillation	
Immunotherapy for	G Protein Inhibitors: Cardiovascular	Inflammation Modul	
Macular Degeneration	CD154 Trimer	5 Lactamase Inhibit	
Screen for Covalent Drugs	Stabilization: Immunity	Malaria Prophylaxis	
Antibiotic-Coated Nanoparticles	AMPA Receptor Antagonists	Nanopariculate Arse Platinum Drugs	
HLD-Like NPs for Inflammation	TGFb Inhibitor Transgene	Herpes Virus Vaccin Oncolvtic Vectors	
CXCR4 Modulators	FFAR2 Agonists for Type 2 Diabetes	Gene Silencing Enha	
Scar-Free Tissue Regeneration	Therapeutic Exosomes	Bladder Regeneratio	
Thermoresponsive Adhesive Dressing	Maspin for Bone Disorders	Glucocerebrosidase Modulators	
Hydrogel Wound Dressing with Cu Ions	Megamolecule Synthetic Antibodies		
Gene Therapy for Anti-Depression	Soft Materials for Bioprinting		

INVO Inventive Activity FY2016 39

PRE-CLINICAL CLINICAL TRIALS APPROVAL

PRE-CLINICAL DEVELOPMENT CLINICALTRIALS APPROVAL Small Molecule CA Thrangy Metallophile Technology for Caucer Lyrca: Fibromyalgia Small Molecule CA Thrangy Small Molecule Shor Lyrca: Fibromyalgia Small Molecule CA Small Molecule CA Small Molecule Shor Lyrca: Fibromyalgia Small Molecule CA Dopaminergic Nerron Hypatochiluro Human Malanoma Tratments for Traumatice NumoardAfe-Carlos Syndrome Qury 1-13 Depression and Qury 1-3 Depression and Qury 1-3 Depression and MMDAR Modulatore GMAI Molecules for Hepatochiluro CA Muman Molecules for Multi Molecules for Banil Molecules for Hepatochiluro CA GMAI Molecules for Cancer Qury 1-3 Depression and Qury 1-3 Depression and Pathibitors GMAI Molecules for Hepatochiluro CA Gene Regulation with Multi Molecules Gene Regulation with Molecules Gene Regulation with Molecules Activity Nitic Code Synthase Inhibitors Minor America Gene Regulation with Molecules Activity Molecules for Molecules Activity Molecules Activity Molecules Attivity Molecules Attivity Molecules Attivity Molecules Attivity Molecules Attivity Gene Regulation with Molecules Attivity Molecules Attivity Molecules A Anti-Tau Monocional Antibodies Sensitization to Steroido Peptides for Immune Tolerance Preventing Allograft Rejection Bladder Regeneration E. coli From Human Prostate Chronic Pevic Pain Vascine Peptide Vascine Against Lupos UTI Symptom Prevention Medical Food for Gi Blattin for Hearing Loss Prevention & Interapy Preventing Scar Preventing Scar Preventing Scar Spherical Nucleic Acids

RESEARCH TOOLS PIPELINE

Available for License Non-Exclusive License/Option Exclusive License/Option

THERAPEUTICS PIPELINE

Available for License Non-Exclusive License/Option Exclusive License/Option

INNOVATION AND NEW VENTURES

invo.northwestern.edu @INVOatNU

1800 Sherman Avenue, Suite 504 Evanston, IL 60201